bf/NASDAQ:BVXV_icon.png

NASDAQ:BVXV

BiondVax Pharmaceuticals Ltd.

  • Stock

USD

Last Close

1.35

06/09 19:59

Market Cap

4.97M

Beta: 2.47

Volume Today

22.67K

Avg: 41.50K

PE Ratio

0.59

PFCF: −3.53

Dec '13
Dec '14
Dec '15
Dec '16
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
average inventory
25.50K
-
25.50K
0%
-291K
1,241.18%
-291K
0%
average payables
398K
-
458K
15.08%
727.50K
58.84%
808.50K
11.13%
3.45M
327.27%
5.86M
69.71%
11.28M
92.44%
8.82M
21.81%
1.84M
79.10%
1.91M
3.66%
average receivables
1.07M
-
752K
29.95%
1.22M
62.63%
1.08M
11.41%
1.97M
81.68%
1.71M
12.90%
302.61K
82.35%
361.72K
19.53%
340.22K
5.94%
208K
38.86%
book value per share
73.41
-
50.76
30.85%
127.16
150.48%
75.84
40.35%
111.93
47.57%
-12.68
111.33%
-79.66
528.15%
-4.10
94.86%
16.53
503.58%
-0.93
105.65%
capex per share
-0.60
-
-0.09
84.69%
-0.13
40.37%
-0.06
54.05%
-8.97
15,047.38%
-36.31
304.81%
-9.10
74.95%
-5.53
39.17%
-0.30
94.49%
-0.44
45.56%
capex to depreciation
-0.28
-
-0.04
83.97%
-0.05
22.18%
-0.03
40.51%
-10.25
31,712.14%
-91.27
790.86%
-4.52
95.05%
-2.52
44.26%
-0.18
92.93%
-1.49
735.45%
capex to operating cash flow
0.05
-
0.00
91.50%
0.00
16.42%
0.00
37.43%
0.45
21,549.61%
0.41
7.50%
0.10
76.77%
0.08
12.32%
0.02
79.22%
0.12
555.22%
capex to revenue
-0.16
-
cash per share
60.83
-
35.59
41.50%
134.52
277.98%
52.47
60.99%
142.03
170.68%
30.83
78.29%
88.74
187.84%
2.64
97.02%
38.28
1,348.03%
7.47
80.50%
days of inventory on hand
days payables outstanding
days sales outstanding
40.64
-
debt to assets
0.89
-
1.13
27.21%
1.18
4.05%
0.70
40.67%
0.80
13.67%
debt to equity
-3.02
-
-2.02
33.24%
-4.60
128.01%
2.99
164.95%
-12.24
509.53%
dividend yield
earnings yield
-0.14
-
-0.12
13.98%
-0.25
105.03%
-0.21
15.74%
-0.36
70.02%
-0.20
44.67%
-0.47
138.12%
0.07
114.40%
-0.49
824.51%
-0.10
80.72%
enterprise value
38.70M
-
53.92M
39.32%
7.24M
86.58%
27.80M
284.18%
24.88M
10.50%
122.20M
391.16%
321.28M
162.91%
118.01M
63.27%
118.66M
0.55%
13.05M
89.00%
enterprise value over ebitda
-5.58
-
-7.22
29.37%
-0.68
90.62%
-2.46
263.61%
-2.02
17.95%
-6.21
207.00%
-4.18
32.67%
33.95
912.22%
-3.66
110.77%
-1.24
66.02%
ev to operating cash flow
-9.20
-
-7.12
22.63%
-0.70
90.10%
-2.88
308.62%
-2.48
14.03%
-2.14
13.69%
-4.17
95.13%
-1.63
60.98%
-4.85
197.90%
-1.80
62.95%
ev to sales
43.18
-
free cash flow per share
-13.47
-
-23.27
72.73%
-39.05
67.83%
-28.64
26.65%
-28.97
1.14%
-123.82
327.46%
-103.46
16.45%
-70.99
31.38%
-17.65
75.14%
-4.30
75.66%
free cash flow yield
-0.08
-
-0.12
53.80%
-0.25
111.49%
-0.22
12.14%
-0.15
31.98%
-0.69
356.19%
-0.32
53.34%
-0.79
144.25%
-0.24
69.23%
-1.45
499.97%
graham net net
56.27
-
32.24
42.70%
109.08
238.31%
40.94
62.47%
96.14
134.85%
-25.00
126.01%
-132.34
429.31%
-17.17
87.03%
-15.59
9.22%
-7.78
50.08%
graham number
201.55
-
164.74
18.26%
332.58
101.88%
215.42
35.23%
416.09
93.16%
100.85
75.76%
521.92
417.55%
23.81
95.44%
115.71
386.04%
2.43
97.90%
income quality
0.52
-
0.98
86.38%
1.01
3.22%
1.05
4.41%
0.29
72.33%
0.65
124.13%
0.71
8.25%
16.28
2,207.30%
0.61
96.24%
1.25
104.67%
intangibles to total assets
0
-
0
0
0
0
0
0
0
0
0
interest coverage
-5.67
-
-5.25
7.34%
0.21
104.07%
-3.22
1,603.11%
2.10
165.34%
interest debt per share
43.86
-
179.03
308.19%
23.24
87.02%
57.08
145.67%
8.63
84.87%
inventory turnover
invested capital
-3.02
-
-2.02
33.24%
-4.60
128.01%
2.99
164.95%
-12.24
509.53%
market cap
56.57M
-
63.53M
12.31%
40.71M
35.93%
43.50M
6.87%
96.26M
121.28%
117.30M
21.85%
262.46M
123.76%
100.06M
61.88%
102.96M
2.90%
5.58M
94.58%
net current asset value
18.53M
-
10.83M
41.53%
29.17M
169.21%
21.64M
25.79%
49.86M
130.36%
-15.99M
132.06%
-107.68M
573.62%
-18.93M
82.42%
-21.22M
12.07%
-14.46M
31.86%
net debt to ebitda
2.58
-
1.29
50.03%
3.14
143.50%
1.39
55.59%
5.80
316.69%
-0.25
104.30%
-0.77
207.03%
5.17
775.09%
-0.48
109.37%
-0.71
46.96%
net income per share
-24.59
-
-23.76
3.38%
-38.66
62.70%
-27.19
29.66%
-68.75
152.82%
-35.64
48.16%
-151.98
326.42%
6.15
104.05%
-36.00
685.34%
-0.28
99.22%
operating cash flow per share
-12.87
-
-23.17
80.07%
-38.92
67.94%
-28.58
26.56%
-20.00
30.03%
-87.51
337.62%
-94.36
7.83%
-65.46
30.63%
-17.35
73.50%
-3.85
77.78%
payables turnover
receivables turnover
8.98
-
research and ddevelopement to revenue
3.76
-
return on tangible assets
-0.31
-
-0.42
35.14%
-0.25
41.29%
-0.31
23.53%
-0.42
38.66%
-0.83
95.99%
-1.07
29.36%
0.39
135.91%
-0.51
232.48%
-0.02
96.15%
revenue per share
1.95
-
roe
-0.34
-
-0.47
39.71%
-0.30
35.05%
-0.36
17.92%
-0.61
71.32%
2.81
557.56%
1.91
32.11%
-1.50
178.70%
-2.18
45.04%
0.30
113.85%
roic
-0.32
-
-0.49
54.09%
-0.34
31.43%
-0.46
37.19%
-0.55
19.79%
-1.37
147.97%
-1.21
11.94%
-0.28
77.04%
-0.44
60.32%
-0.05
89.27%
sales general and administrative to revenue
8.73
-
shareholders equity per share
73.41
-
50.76
30.85%
127.16
150.48%
75.84
40.35%
111.93
47.57%
-12.68
111.33%
-79.66
528.15%
-4.10
94.86%
16.53
503.58%
-0.93
105.65%
stock based compensation to revenue
3.24
-
tangible asset value
23.99M
-
16.59M
30.85%
33.55M
102.24%
25.62M
23.64%
56.25M
119.60%
-8.29M
114.73%
-65.05M
684.89%
-4.54M
93.02%
23.33M
614.03%
-1.76M
107.54%
tangible book value per share
73.41
-
50.76
30.85%
127.16
150.48%
75.84
40.35%
111.93
47.57%
-12.68
111.33%
-79.66
528.15%
-4.10
94.86%
16.53
503.58%
-0.93
105.65%
working capital
18.58M
-
10.90M
41.37%
35.23M
223.32%
24.76M
29.71%
68.42M
176.30%
14.62M
78.64%
54.16M
270.57%
-16.66M
130.75%
47.84M
387.20%
12.03M
74.85%

All numbers in USD (except ratios and percentages)